Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Immunotherapy treatments with anti-PD-1 boost recovery in less than 30% of treated cancer patients, indicating the complexity of the tumor microenvironment. Expression of HLA-E is linked to poor clinical outcomes in mice and human patients. However, the contributions to immune evasion of HLA-E, a ligand for the inhibitory CD94/NKG2A receptor, when expressed on tumors, compared with adjacent tissue and peripheral blood mononuclear cells, remains unclear. In this study, we report that epithelial-derived cancer cells, tumor macrophages, and CD141+ conventional dendritic cells (cDC) contributed to HLA-E enrichment in carcinomas. Different cancer types showed a similar pattern of enrichment. Enrichment correlated to NKG2A upregulation on CD8+ tumor-infiltrating T lymphocytes (TIL) but not on CD4+ TILs. CD94/NKG2A is exclusively expressed on PD-1high TILs while lacking intratumoral CD103 expression. We also found that the presence of CD94/NKG2A on human tumor–specific T cells impairs IL2 receptor–dependent proliferation, which affects IFNγ-mediated responses and antitumor cytotoxicity. These functionalities recover following antibody-mediated blockade in vitro and ex vivo. Our results suggest that enriched HLA-E:CD94/NKG2A inhibitory interaction can impair survival of PD-1high TILs in the tumor microenvironment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“However, other murine studies have also shown that tumor APCs can be dysregulated to become tolerogenic, a process driven by immunosuppressive factors such as IL10 and β-catenin (26, 27, 34, 35).”
BackgroundBatf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081 · cited 1×
“For instance, the inhibitory PD-1/PD-L-1 axis was upregulated on murine tumor APC and contributed to progressively growing tumor (28, 36, 37).”
BackgroundAhmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370 · cited 1×
“It is most likely that any NKG2A coexpression with CD103 could be present on viral-specific tumor-infiltrating T lymphocytes, whereby another study has highlighted the overabundance of bystander viral-specific T cells in tumor that do not recognize tumor neoantigens and therefore might not have antitumor immune capaci…”
BackgroundThommen, D. S., Koelzer, V. H., Herzig, P., Roller, A., Trefny, M., Dimeloe, S., Kiialainen, A., Hanhart, J., Schill, C., Hess, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0057-z · Cited by 1,161
Dynamic T cell migration program provides resident memory within intestinal epithelium
Masopust, D., Choo, D., Vezys, V., Wherry, E. J., Duraiswamy, J., Akondy, R., Wang, J., Casey, K. A., Barber, D. L., Kawamura, K. S., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20090858 · Cited by 628
Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402711 · Cited by 622
Leone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553
Cited by
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
An NK-like CAR T cell transition in CAR T cell dysfunction
Good, C. R., Aznar, M. A., Kuramitsu, S., Samareh, P., Agarwal, S., Donahue, G., Ishiyama, K., Wellhausen, N., Rennels, A. K., Ma, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.11.016 · Cited by 396
High-definition spatial transcriptomic profiling of immune cell populations in colorectal cancer
Oliveira, M. F. D., Romero, J. P., Chung, M., Williams, S. R., Gottscho, A. D., Gupta, A., Pilipauskas, S. E., Mohabbat, S., Raman, N., Sukovich, D. J., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02193-3 · Cited by 321
Monalizumab: inhibiting the novel immune checkpoint NKG2A
van Hall, T., André, P., Horowitz, A., Ruan, D. F., Borst, L., Zerbib, R., Narni-Mancinelli, E., van der Burg, S. H., & Vivier, E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0761-3 · Cited by 292
Jiang, H., Yu, D., Yang, P., Guo, R., Kong, M., Gao, Y., Yu, X., Lu, X., & Fan, X. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.730 · Cited by 255
Metadata
- Authors
- Abd Hamid, M., Wang, R.-Z., Yao, X., Fan, P., Li, X., Chang, X.-M., Feng, Y., Jones, S., Maldonado-Perez, D., Waugh, C., Verrill, C., Simmons, A., Cerundolo, V., McMichael, A., Conlon, C., Wang, X., Peng, Y., & Dong, T.
- Venue
- Cancer Immunology Research
- Published
- 2019-08-01
- Volume
- 7
- Issue
- 8
- Pages
- 1293-1306
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- OpenAlex
- W2950180668
- Cited by
- 86
- References
- 8
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0885
- The paper
- Abd Hamid, M., Wang, R.-Z., Yao, X., Fan, P., Li, X., Chang, X.-M., Feng, Y., Jones, S., Maldonado-Perez, D., Waugh, C., Verrill, C., Simmons, A., Cerundolo, V., McMichael, A., Conlon, C., Wang, X., Peng, Y., & Dong, T. (2019). Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0885
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.